LifeStance Health Group, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 9, 2023 and accepted by EDGAR at Aug 9, 2023, 20:26 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $259.6m | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $512.2m | us-gaap:Revenues |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $101.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $186.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$48.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$82.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $5.1m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $10.2m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | −$6.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | −$10.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$45.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$79.7m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 363,161 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 362,039 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$8.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $19.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $79.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $237.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $2.17bn | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $180.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $676.0m | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $248.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-06-30 | $2.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-06-30 | $1.49bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-040649. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.